Skip to main content

Table 1 Characteristics of donor groups enrolled into the study

From: Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study

Group/parameter

Healthy control

Cancer patients (all cases)

Patients with locally advanced cancer

Patients with metastatic cancer

No spread

Spread

Number (n)

50

53

19

16

18

Sex (M/F)

30/20

37/16

12/7

13/3

12/6

Age (years)

28–60 (median 50)

34–74 (median 59)

36–70 (median 59)

34–73 (median 58)

35–74 (median 60)

Tumor location

 Upper third

–

15 (28 %)

3 (16 %)

6 (37 %)

6 (33 %)

 Middle third

–

31 (59 %)

13 (68 %)

9 (57 %)

9 (50 %)

 Lower third

–

7 (13 %)

3 (16 %)

1 (6 %)

3 (17 %)

Histological grade

 G1–G2

–

16 (30 %)

10 (53 %)

3 (19 %)

3 (17 %)

 G3

–

29 (55 %)

8 (42 %)

11 (69 %)

10 (56 %)

 Not specified

–

8 (15 %)

1 (5 %)

2 (12 %)

5 (27 %)

Primary tumor

 cT1–T3

–

50 (94 %)

19 (100 %)

16 (100 %)

15 (83 %)

 cT4

–

3 (6 %)

0 (0 %)

0 (0 %)

3 (17 %)

Lymph node

 cN0

–

20 (38 %)

13 (68 %)

5 (31 %)

2 (11 %)

 cN1–N3

–

33 (62 %)

6 (32 %)

11 (69 %)

16 (89 %)

Metastasis (initial)

 cM0

–

35 (66 %)

19 (100 %)

16 (100 %)

0 (0 %)

 cM1

–

18 (34 %)

0 (0 %)

0 (0 %)

18 (100 %)

  1. Group of patients with locally advanced cancer at time of diagnosis were further split into subgroup where either no spread (control) or consecutive cancer dissemination/spread (distant metastasis) was detected